About Genmab
Genmab is a publicly listed company based in Copenhagen (Denmark) founded in 1999 by Jan van de Winkel. Antibody therapeutics for cancer and autoimmune diseases are developed. The company has 2,680 employees. Genmab has completed 2 acquisitions, including Merus and Profound Bio. Its chief executive, as recorded, is Jan van de Winkel. Its website genmab.com draws about 124 thousand monthly visits. Its focus areas include Life Sciences, Immunotherapy, Antibody and Immunomodulatory.
Company details
Genmab was established in 1999 in Copenhagen, Denmark, within the biotechnology sector. Antibody-based treatments for cancer and autoimmune conditions are created using proprietary platforms such as DuoBody, HexaBody, DuoHexaBody, and HexElect. A product pipeline is maintained, featuring items like Teprotumumab for thyroid eye disease, Tisotumab vedotin for certain solid tumors and cervical cancer, and Darzalex for multiple myeloma, with operations centered on research and development.
- Headquarters Copenhagen, Denmark
- Employees 2,680
- Founders Jan van de Winkel
- Stage Public
- SectorsHealthcare
- Website genmab.com
- Social LinkedIn
- Legal Name Genmab A/S
Funding Insights of Genmab
- Total Rounds 3
- Last Round Post-IPO — $181.27M
- First Round $23M
(Oct 2009)
- Investors Count 1
All 3 funding rounds of Genmab with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2014 | $181.27M | Post-IPO | – | – | – |
| Jul 2010 | $134M | Post-IPO | – | – | – |
| Oct 2009 | $23M | Post-IPO | – | – |
1 investors in total: 1 institutional.
Investors in Genmab
Genmab has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include GSK.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Developer of pharmaceuticals and vaccines for various therapeutic areas | 1715 | gsk.com | Brentford, United Kingdom |
Investor details for Genmab
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Genmab
300 people are tracked at Genmab (181 in leadership, 8 in board & advisors, 111 in team); the tracked headcount is 2,680.
| Name | Role | Group |
|---|---|---|
Jan van de Winkel | Co-Founder & CEO | Leadership |
Tracy Haefner | Director, Global Human Resources Business Partner, Development | Leadership |
Sneh Lata | Associate Director, Translational Data Sciences | Leadership |
Mashu Watanabe | Associate Director - Fp&a, Commercial Lead | Leadership |
Birgitte Stephensen | Executive Vice President & Chief Legal Officer | Leadership |
Scott Frederick | Director, Digital Products, Commercialization Operations | Leadership |
Catherine Liu | Senior Finance Director Corporate Financial Planning And Analysis | Leadership |
Marisol Peron | Corporate VP, Communications & Investor Relations | Leadership |
Tahamtan Ahmadi | CMO & Head, Experimental Medicines | Leadership |
Anthony Pagano | EVP & CFO | Leadership |
Jeremy Yoder | Regional Business Director - Genmab | Leadership |
Kristin Strumane | Associate Director, Translational Research | Leadership |
Kristel Kemper | Director, Translational Research | Leadership |
Jeffrey R. Harris | Director, Translational Medicine Lead, ADC Development | Leadership |
Courtney Sellani | Associate Director, Commercialization Operations & Business Effectiveness | Leadership |
Justin Geissler | Associate Director, Fp&a | Leadership |
Naga L G Deepika Dhanvadha Venkatha | Director, HR Business Effectiveness | Leadership |
Kim Santegoets | Associate Director Translational Research | Leadership |
Jan G. J. van de Winkel | President & CEO | Leadership |
Nian Gong | Clinical Research Scientist, Director | Leadership |
280 more people are available in the full profile.
Complete people profiles for Genmab
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Genmab
Genmab is a publicly listed company on the OMXCOP with ticker symbol GMAB in Denmark, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date07 Jun 2013
- Listed onNASDAQ: GMAB
- Listed entityGenmab A/S
- Exchange sectorHealth technology
- ISINDK0010272202
- Share price2,453.00 DKK (-0.69% on the day) · 2026-10-14
- Market capitalisation147,623,882,751.00 DKK
- Price to earnings30.3
- EPS (diluted, trailing year)81.07 DKK
- Volume (last session)27,631
Financials of Genmab
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 24.60B DKK | 6.37B DKK | 8.74B DKK |
| 2024 | 21.53B DKK | 7.84B DKK | 7.42B DKK |
| 2023 | 16.47B DKK | 4.35B DKK | 5.65B DKK |
| 2022 | 14.51B DKK | 5.45B DKK | 6.59B DKK |
| 2021 | 8.48B DKK | 3.01B DKK | 3.27B DKK |
Detailed financial statements for Genmab
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Genmab
Genmab has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Merus and Profound Bio.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Antibody-based drugs for cancer treatment are developed using bispecific engineering. | merus.nl | Utrecht, Netherlands | 2003 | Dec 2025 | $6.9B | |
Novel cancer therapies are developed via antibody-drug conjugates. | profoundbio.com | Woodinville, United States | 2018 | Apr 2024 | $1.8B |
Complete acquisition details for Genmab
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Genmab
6 dated milestones of Genmab across 26 years, from founding to its latest funding, stage changes and deals.
- Founded Genmab is founded.
- Funding First funding round of $23.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $181.3M.
- Acquisition Acquires Profound Bio.
- Acquisition Acquires Merus.
Web traffic of Genmab
The website of Genmab (genmab.com) receives about 124K visits a month.
- Monthly visits124K
▲ 5.1% vs previous month
Websites whose visitors overlap most with Genmab. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| lifediagnostics.com | 100% | #4,117,402 | View details | ||
| mainebiotechnology.com | 100% | View details | |||
ancell.com | ancell.com | 100% | #5,981,503 | – | |
| diatec.com | 100% | 1.3K | #13,680,897 | View details | |
| rockland-inc.com | 100% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 19 similar websites and full traffic analytics for Genmab
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 19 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Genmab
Complete news archive for Genmab
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genmab
Genmab was founded in 1999 and raised its 1st funding round 10 years after it was founded.
Genmab is headquartered in Copenhagen, Denmark.
Jan van de Winkel is the CEO of Genmab, as recorded in our data. They have also founded this company.
Genmab has 2,680 employees.
Annual revenue of Genmab is $3.87B as on Dec 31, 2025.
Genmab was established in 1999 in Copenhagen, Denmark, within the biotechnology sector. Antibody-based treatments for cancer and autoimmune conditions are created using proprietary platforms such as DuoBody, HexaBody, DuoHexaBody, and HexElect. A product pipeline is maintained, featuring items like Teprotumumab for thyroid eye disease, Tisotumab vedotin for certain solid tumors and cervical cancer, and Darzalex for multiple myeloma, with operations centered on research and development.
Yes, Genmab is publicly traded on OMXCOP under the ticker symbol GMAB.
Genmab has made 2 acquisitions, including Merus, and Profound Bio.
Genmab has 1 investor. Key investors include GSK.
The website of Genmab receives about 124 thousand visits a month.